FDA Okays Drug for Frequent Nocturia
By medpagetoday.com
For the first time the FDA approved a treatment for frequent nighttime urination due to overproduction of urine.
The drug, desmopressin acetate (Noctiva), is delivered as a nasal spray and is approved for use only in adults who awaken two or more times nightly to urinate due to nocturnal polyuria. Used daily "approximately 30 minutes before going to bed, it works by increasing the absorption of water through the kidneys, which leads to less urine production," the agency said.
In a statement, Hylton V. Joffe, MD, MMSc, of the FDA's Center for Drug Evaluation and Research, said, "It is important to know that Noctiva is not approved for all causes of nighttime urination, so patients should discuss their symptoms with their healthcare provider who can determine the underlying cause of the nighttime urination and whether Noctiva is right for them."
The FDA cautioned that nocturia can be caused by a wide variety of conditions, "such as congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate. Before considering Noctiva, healthcare providers should evaluate each patient for possible causes for the nocturia, and optimize the treatment of underlying conditions that may be contributing to the nighttime urination. Because Noctiva is approved only for adults with nocturia caused by nocturnal polyuria, healthcare providers should confirm overproduction of urine at night with a 24-hour urine collection, if one has not been obtained previously."
Moreover, the FDA warned that underlying conditions, including congestive heart failure, could make use of the drug unsafe.
Noctiva is taken daily, approximately 30 minutes before going to bed. It works by increasing the absorption of water through the kidneys, which leads to less urine production.
The approval was based on two 12-week, randomized, placebo-controlled trials in 1,045 patients 50 years of age and older with nocturia due to nocturnal polyuria. Both studies demonstrated only a small benefit compared with placebo, but "more patients treated with Noctiva were able to at least halve their number of nighttime urinations, and patients treated with Noctiva had more nights with one or fewer night-time urinations."
The drug will carry a boxed warning that it can cause hyponatremia, which can be life-threatening if severe.
"Noctiva should not be used in patients at increased risk of severe hyponatremia, such as those with excessive fluid intake, those who have illnesses that can cause fluid or electrolyte imbalances, certain patients with kidney damage, and in those using certain medicines, known as loop diuretics or glucocorticoids," the FDA said. The drug should not be used in pregnant women or children.
Side effects included nasal discomfort, nasal congestion, sneezing, hypertension, nose bleeds, bronchitis, and dizziness.
Noctiva is marketed by Milford, Pennsylvania-based Renaissance Lakewood, LLC for Serenity Pharmaceuticals, LLC.
Source: http://www.medpagetoday.com/urology/urology/63578
cialis grapefruitsaft http://cialissom.com/ chemical formula of cialis cialis online which works best viagra or cialis cialis cheap 5 mg cialis cost http://cialisles.com/ cialis-generico-en-espana.blogspot.com
Sunday, May 31, 2026
Treating Cancer With Antabuse: Key Facts
When a person is diagnosed with cancer or seeks relief from it, selecting the most appropriate medication requires weighing multiple factors: the severity of symptoms, the patient's age and health history, and whether other medications are already being taken. A thoughtful treatment choice improves outcomes and reduces unnecessary side effects. The spectrum of allergic disease is broad. Seasonal allergic rhinitis, often called hay fever, flares in response to outdoor allergens such as tree pollen in spring and ragweed in fall. Perennial allergies occur year-round and are typically triggered by indoor allergens like dust mites and pet dander. Chronic urticaria manifests as persistent hives and can last months or years without a clearly identifiable cause. All of these conditions share a common inflammatory pathway driven by the immune system's release of chemical mediators. Among the medications available for dependence, Antabuse provides a well-studied option that many patients discuss with their doctors. The clinical evidence supporting antabuse for cancer shows that it can be effective for managing this condition when used appropriately under medical supervision. Antabuse contains the active ingredient disulfiram, which works by acting on the biological pathways responsible for producing the symptoms associated with cancer. Understanding the mechanism helps patients appreciate why consistent use is often more effective than taking it only when symptoms become severe, as maintaining steady levels allows for more stable control. Patients managing cancer long-term should keep regular follow-up appointments to assess whether their treatment plan is still the best fit for their situation. As conditions change and new evidence emerges, treatment adjustments may be worthwhile. The https://mednewwsstoday.com/dependence/ resource section provides a helpful reference for staying current on medication options in this area.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.